Pfizer (PFE) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $0.62.
- Pfizer's EPS (Weighted Average and Diluted) fell 2151.9% to $0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.44, marking a year-over-year increase of 22105.26%. This contributed to the annual value of $0.0 for FY2024, which is 9947.84% down from last year.
- As of Q3 2025, Pfizer's EPS (Weighted Average and Diluted) stood at $0.62, which was down 2151.9% from $0.51 recorded in Q2 2025.
- Over the past 5 years, Pfizer's EPS (Weighted Average and Diluted) peaked at $1.73 during Q3 2022, and registered a low of -$0.59 during Q4 2023.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was $0.54 (2024), whereas its average is $0.53.
- In the last 5 years, Pfizer's EPS (Weighted Average and Diluted) plummeted by 12781.46% in 2023 and then soared by 31488500.0% in 2024.
- Over the past 5 years, Pfizer's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.0 in 2021, then soared by 66598.08% to $1.51 in 2022, then tumbled by 139.07% to -$0.59 in 2023, then skyrocketed by 233.9% to $0.79 in 2024, then decreased by 21.52% to $0.62 in 2025.
- Its last three reported values are $0.62 in Q3 2025, $0.51 for Q2 2025, and $0.52 during Q1 2025.